Resultados da busca - Patrick Vermersch

Refinar Resultados
  1. 1
    Social participation in patients with multiple sclerosis: correlations between disability and economic burden

    Social participation in patients with multiple sclerosis: correlations between disability and economic burden por Arnaud Kwiatkowski, Jean-Pierre Marissal, Madani Pouyfaucon, Patrick Vermersch, Patrick Hautecœur, B. Dervaux

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.

    Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. por D Caparros-Lefèbvre, S. Blond, Patrick Vermersch, N. Pécheux, J.D. Guieu, H Petit

    Publicado em 1993
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose? por Patrick Vermersch, Jeremy Hobart, Catherine Dive‐Pouletty, Sylvie Bozzi, Steven Hass, Patricia K. Coyle

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Diagnosis and treatment of progressive multiple sclerosis: A position paper

    Diagnosis and treatment of progressive multiple sclerosis: A position paper por Carlo Pozzilli, Maura Pugliatti, Patrick Vermersch, Nikolaos Grigoriadis, Mona Alkhawajah, Laura Airas, Celia Oreja‐Guevara

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  5. 5
    Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients

    Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients por Floriane Calocer, Olivier Dejardin, Arnaud Kwiatkowski, Bertrand Bourre, Patrick Vermersch, Patrick Hautecœur, Guy Launoy, Gilles Defer

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis

    Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis por Anne Helme, Dipak Kalra, Giampaolo Brichetto, Guy Peryer, Patrick Vermersch, Helga Weiland, Angela White, Paola Zaratin

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

    Clinical effects of natalizumab on multiple sclerosis appear early in treatment course por Ludwig Kappos, Paul O’Connor, Christopher H. Polman, Patrick Vermersch, Heinz Wiendl, Amy Pace, Annie Zhang, Christophe Hotermans

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

    Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study por Patrick Vermersch, R. Benrabah, Nicolás Schmidt, Hélène Zephir, Pierre Clavelou, Cyrille Vongsouthi, Patrice Dubreuil, Alain Moussy, Olivier Hermine

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

    Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study por Cristoforo Comi, Stuart D. Cook, Kottil Rammohan, Per Soelberg Sørensen, Patrick Vermersch, Abidemi Adeniji, Fernando Dangond, Gavin Giovannoni

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype por Bruno Brochet, Pierre Clavelou, Gilles Defer, de Sèze, Céline Louapre, Éloi Magnin, Aurélie Ruet, Catherine Thomas-Antérion, Patrick Vermersch

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  11. 11
    Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

    Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study por Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Gıancarlo Comı, Fernando Dangond, Abidemi Adeniji, Patrick Vermersch

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study por Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Gıancarlo Comı, Fernando Dangond, Christine Hicking, Patrick Vermersch

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder?

    Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? por Didier Leys, Jean‐Pierre Pruvo, Maxime Parent, Patrick Vermersch, G Soetaert, M Steinling, A. Delacourte, A. Défossez, A. Rapoport, J Clarisse

    Publicado em 1991
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Neurologic Manifestations in Primary Sjögren Syndrome

    Neurologic Manifestations in Primary Sjögren Syndrome por S. Delalande, de Sèze, A.L. Fauchais, É. Hachulla, Tanya Stojkovic, D. Ferriby, Sylvain Dubucquoi, Jean‐Pierre Pruvo, Patrick Vermersch, Pierre‐Yves Hatron

    Publicado em 2004
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

    Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. por Philip Scheltens, Didier Leys, Frederik Barkhof, D. Huglo, H. C. Weinstein, Patrick Vermersch, Michaël Kuiper, M Steinling, Erik Ch. Wolters, Jaap Valk

    Publicado em 1992
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

    Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis por Gıancarlo Comı, Stuart D. Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Andrew Galazka, Axel Nolting, Christine Hicking, Fernando Dangond

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

    Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review por Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, Patrick Vermersch, Hans‐Peter Hartung, Letizia Leocani, Thomas Berger, Bart Van Wijmeersch, Celia Oreja‐Guevara

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  18. 18
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper por Susana Otero-Romero, Jaume Sastre‐Garriga, Cristoforo Comi, Hans-Peter Hartung, Per Soelberg Sørensen, Alan J. Thompson, Patrick Vermersch, Ralf Gold, Xavier Montalbán

    Publicado em 2016
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  19. 19
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial por Jerry S. Wolinsky, Xavier Montalbán, Stephen L. Hauser, Gavin Giovannoni, Patrick Vermersch, Corrado Bernasconi, Gurpreet Deol‐Bhullar, Hideki Garren, Peter Chin, Shibeshih Belachew, Ludwig Kappos

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

    A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis por Gavin Giovannoni, Gıancarlo Comı, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven J. Greenberg

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: